Ayala Pharmaceuticals Inc. (AYLA): Price and Financial Metrics
AYLA Price/Volume Stats
| Current price | $0.50 | 52-week high | $7.31 |
| Prev. close | $0.48 | 52-week low | $0.36 |
| Day low | $0.44 | Volume | 137,700 |
| Day high | $0.57 | Avg. volume | 76,300 |
| 50-day MA | $0.53 | Dividend yield | N/A |
| 200-day MA | $1.37 | Market Cap | 7.46M |
AYLA Stock Price Chart Interactive Chart >
Ayala Pharmaceuticals Inc. (AYLA) Company Bio
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Latest AYLA News From Around the Web
Below are the latest news stories about AYALA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AYLA as an investment opportunity.
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingREHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (C |
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsREHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibito |
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue EstimatesAyala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateEntered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated substantial anti-tumor activity for AL102 as monotherapy and supports continued development AL102 granted Fast Track designation by U.S. FDA for the treatment of progressing desmoid tumors REHOVOT, Israel |
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQAyala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement. The merger would result in a combined company focusing predominantly on developing and commercializing Ayala's lead program AL102 to treat desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer. Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors. The combined company has the cash to advance the combined p |
AYLA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -95.27% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -95.30% |
| 2021 | -22.64% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...